Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
Abstract Objectives To explore the drug susceptibility of levofloxacin (LFX), moxifloxacin (MFX), bedaquiline (BDQ), linezolid (LZD), clofazimine (CFZ) and delamanid (DLM) against multidrug resistant tuberculosis (MDR-TB) isolates from drug resistance survey of southwest China, and to illustrate the...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12879-021-06024-8 |
id |
doaj-d0ad21e9d229484293b39955f51e823e |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Huiwen Zheng Wencong He Weiwei Jiao Hui Xia Lin Sun Shengfen Wang Jing Xiao Xichao Ou Yanlin Zhao Adong Shen |
spellingShingle |
Huiwen Zheng Wencong He Weiwei Jiao Hui Xia Lin Sun Shengfen Wang Jing Xiao Xichao Ou Yanlin Zhao Adong Shen Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China BMC Infectious Diseases Mycobacterium tuberculosis Drug resistance Mutation |
author_facet |
Huiwen Zheng Wencong He Weiwei Jiao Hui Xia Lin Sun Shengfen Wang Jing Xiao Xichao Ou Yanlin Zhao Adong Shen |
author_sort |
Huiwen Zheng |
title |
Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China |
title_short |
Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China |
title_full |
Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China |
title_fullStr |
Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China |
title_full_unstemmed |
Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China |
title_sort |
molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of china |
publisher |
BMC |
series |
BMC Infectious Diseases |
issn |
1471-2334 |
publishDate |
2021-04-01 |
description |
Abstract Objectives To explore the drug susceptibility of levofloxacin (LFX), moxifloxacin (MFX), bedaquiline (BDQ), linezolid (LZD), clofazimine (CFZ) and delamanid (DLM) against multidrug resistant tuberculosis (MDR-TB) isolates from drug resistance survey of southwest China, and to illustrate the genetic characteristics of MDR-TB isolates with acquired drug resistance. Methods A total of 339 strains were collected from smear-positive TB patients in the drug resistance survey of southwest China between January 2014 and December 2016. The MICs for the above mentioned drugs were determined for MDR-TB by conventional drug susceptibility testing. Genes related to drug resistance were amplified with their corresponding pairs of primers. Results MDR was observed in 88 (26.0%; 88/339) isolates. LFX had the highest resistance rate (50.0%; 44/88), followed by MFX (38.6%; 34/88). The resistance rate to LZD, CFZ, and DLM was 4.5% (4/88), 3.4% (3/88), and 4.5% (4/88), respectively, and the lowest resistance rate was observed in BDQ (2.3%; 2/88). Of the 45 isolates resistant to LFX and MFX, the most prevalent resistance mutation was found in gyrA with the substitution of codon 94 (34/45, 75.6%). Two strains with CFZ - BDQ cross resistance had a mutation in the Rv0678 gene. Of the four LZD resistant isolates, two carried mutations in rplC gene. For the four isolates resistant to DLM, one isolate had mutations in codon 318 of fbiC gene, and two isolates were with mutations in codon 81 of ddn gene. Conclusion This study provided evidence of the usefulness of new anti-TB drugs in the treatment of MDR-TB in China. |
topic |
Mycobacterium tuberculosis Drug resistance Mutation |
url |
https://doi.org/10.1186/s12879-021-06024-8 |
work_keys_str_mv |
AT huiwenzheng molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina AT wenconghe molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina AT weiweijiao molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina AT huixia molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina AT linsun molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina AT shengfenwang molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina AT jingxiao molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina AT xichaoou molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina AT yanlinzhao molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina AT adongshen molecularcharacterizationofmultidrugresistanttuberculosisagainstlevofloxacinmoxifloxacinbedaquilinelinezolidclofazimineanddelamanidinsouthwestofchina |
_version_ |
1721531425826537472 |
spelling |
doaj-d0ad21e9d229484293b39955f51e823e2021-04-11T11:08:30ZengBMCBMC Infectious Diseases1471-23342021-04-012111610.1186/s12879-021-06024-8Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of ChinaHuiwen Zheng0Wencong He1Weiwei Jiao2Hui Xia3Lin Sun4Shengfen Wang5Jing Xiao6Xichao Ou7Yanlin Zhao8Adong Shen9Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthNational Tuberculosis Reference Laboratory, Chinese Center for Disease Control and PreventionBeijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthNational Tuberculosis Reference Laboratory, Chinese Center for Disease Control and PreventionBeijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthNational Tuberculosis Reference Laboratory, Chinese Center for Disease Control and PreventionBeijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthNational Tuberculosis Reference Laboratory, Chinese Center for Disease Control and PreventionNational Tuberculosis Reference Laboratory, Chinese Center for Disease Control and PreventionBeijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s HealthAbstract Objectives To explore the drug susceptibility of levofloxacin (LFX), moxifloxacin (MFX), bedaquiline (BDQ), linezolid (LZD), clofazimine (CFZ) and delamanid (DLM) against multidrug resistant tuberculosis (MDR-TB) isolates from drug resistance survey of southwest China, and to illustrate the genetic characteristics of MDR-TB isolates with acquired drug resistance. Methods A total of 339 strains were collected from smear-positive TB patients in the drug resistance survey of southwest China between January 2014 and December 2016. The MICs for the above mentioned drugs were determined for MDR-TB by conventional drug susceptibility testing. Genes related to drug resistance were amplified with their corresponding pairs of primers. Results MDR was observed in 88 (26.0%; 88/339) isolates. LFX had the highest resistance rate (50.0%; 44/88), followed by MFX (38.6%; 34/88). The resistance rate to LZD, CFZ, and DLM was 4.5% (4/88), 3.4% (3/88), and 4.5% (4/88), respectively, and the lowest resistance rate was observed in BDQ (2.3%; 2/88). Of the 45 isolates resistant to LFX and MFX, the most prevalent resistance mutation was found in gyrA with the substitution of codon 94 (34/45, 75.6%). Two strains with CFZ - BDQ cross resistance had a mutation in the Rv0678 gene. Of the four LZD resistant isolates, two carried mutations in rplC gene. For the four isolates resistant to DLM, one isolate had mutations in codon 318 of fbiC gene, and two isolates were with mutations in codon 81 of ddn gene. Conclusion This study provided evidence of the usefulness of new anti-TB drugs in the treatment of MDR-TB in China.https://doi.org/10.1186/s12879-021-06024-8Mycobacterium tuberculosisDrug resistanceMutation |